To comprehensively characterize tumor biopsy tissue, clinical assays were performed within the OHSU Knight Diagnostic Laboratories that are CLIA-licensed/CAP-accredited, including IHC (ER, PR, HER2, AR, and PD-L1), a targeted next-generation sequencing (NGS) panel covering 125 genes (GeneTrails© Comprehensive Solid Tumor Panel), whole transcriptomic sequencing (Illumina TruSeq RNA exome), and a multiplex protein analysis of 22 key cancer proteins and phosphoproteins (the Intracellular Signaling Protein Panel) developed on the NanoString Vantage 3DTM Solid Tumor Panel. This evidence concerns the gene ESR1 and neoplasm.